-
3
-
-
0036024584
-
Ovarian cancer: Progress and continuing controversies in management
-
Moss C, Kaye SB. Ovarian cancer: progress and continuing controversies in management. Eur J Cancer 2002;38:1701-7.
-
(2002)
Eur J Cancer
, vol.38
, pp. 1701-1707
-
-
Moss, C.1
Kaye, S.B.2
-
4
-
-
0036711606
-
Part I: Chemotherapy for epithelial ovarian cancer - Treatment at first diagnosis
-
Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer - treatment at first diagnosis. Lancet Oncol 2002;3:529-36.
-
(2002)
Lancet Oncol
, vol.3
, pp. 529-536
-
-
Harries, M.1
Gore, M.2
-
5
-
-
0036089979
-
Docetaxel: Pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model
-
DOI 10.1007/s00280-002-0439-1
-
Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol 2002;49:499-503. (Pubitemid 34671286)
-
(2002)
Cancer Chemotherapy and Pharmacology
, vol.49
, Issue.6
, pp. 499-503
-
-
Marchettini, P.1
Stuart, O.A.2
Mohamed, F.3
Yoo, D.4
Sugarbaker, P.H.5
-
6
-
-
40749086094
-
Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer
-
Howell SB. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int J Gynecol Cancer 2008;18:20-5.
-
(2008)
Int J Gynecol Cancer
, vol.18
, pp. 20-25
-
-
Howell, S.B.1
-
7
-
-
30044438368
-
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
-
DOI 10.1056/NEJMoa052985
-
Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med 2006;354:34-43. (Pubitemid 43048949)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.1
, pp. 34-43
-
-
Armstrong, D.K.1
Bundy, B.2
Wenzel, L.3
Huang, H.Q.4
Baergen, R.5
Lele, S.6
Copeland, L.J.7
Walker, J.L.8
Burger, R.A.9
Mackey, D.10
-
8
-
-
33748328355
-
Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: From laboratory bench to bedside
-
DOI 10.1016/j.ctrv.2006.07.006, PII S030573720600137X
-
de Bree E, Theodoropoulos PA, Rosing H, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev 2006;32:471-82. (Pubitemid 44321352)
-
(2006)
Cancer Treatment Reviews
, vol.32
, Issue.6
, pp. 471-482
-
-
De Bree, E.1
Theodoropoulos, P.A.2
Rosing, H.3
Michalakis, J.4
Romanos, J.5
Beijnen, J.H.6
Tsiftsis, D.D.7
-
9
-
-
29144462090
-
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study
-
DOI 10.1016/j.ygyno.2005.11.013, PII S0090825805010012
-
Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intrapentoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006;100:27-32. (Pubitemid 41815045)
-
(2006)
Gynecologic Oncology
, vol.100
, Issue.1
, pp. 27-32
-
-
Walker, J.L.1
Armstrong, D.K.2
Huang, H.Q.3
Fowler, J.4
Webster, K.5
Burger, R.A.6
Clarke-Pearson, D.7
-
10
-
-
0035214416
-
Metronomic scheduling: The future of chemotherapy?
-
Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001;2:733-40.
-
(2001)
Lancet Oncol
, vol.2
, pp. 733-740
-
-
Gasparini, G.1
-
11
-
-
41649097550
-
Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer
-
DOI 10.1158/1535-7163.MCT-07-2117
-
Vassileva V, Piquette-Miller M. Ovarian tumour repopulation in response to sustained and intermittent paclitaxel therapy. Clin Pharmacol Ther 2008;83:S52-S. (Pubitemid 351482145)
-
(2008)
Molecular Cancer Therapeutics
, vol.7
, Issue.3
, pp. 630-637
-
-
Vassileva, V.1
Allen, C.J.2
Piquette-Miller, M.3
-
12
-
-
33644986064
-
Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: Repopulation as a cause of treatment failure?
-
Brade AM, Tannock IF. Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? J Clin Oncol 2006;24:1020-2.
-
(2006)
J Clin Oncol
, vol.24
, pp. 1020-1022
-
-
Brade, A.M.1
Tannock, I.F.2
-
13
-
-
57449102025
-
Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging
-
Vassileva V, Moriyama EH, De Souza R, et al. Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging. Brit J Cancer 2008; 99:2037-43.
-
(2008)
Brit J Cancer
, vol.99
, pp. 2037-2043
-
-
Vassileva, V.1
Moriyama, E.H.2
De Souza, R.3
-
14
-
-
34548563731
-
Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model
-
DOI 10.1007/s00280-007-0449-0
-
Vassileva V, Grant J, De Souza R, Allen C, Piquette-Miller M. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemother Pharmacol 2007;60: 907-14. (Pubitemid 47389398)
-
(2007)
Cancer Chemotherapy and Pharmacology
, vol.60
, Issue.6
, pp. 907-914
-
-
Vassileva, V.1
Grant, J.2
De Souza, R.3
Allen, C.4
Piquette-Miller, M.5
-
16
-
-
67649664258
-
Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity
-
Zahedi P, De Souza R, Piquette-Miller M, Allen C. Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity. Int J Pharm 2009;377:76-84.
-
(2009)
Int J Pharm
, vol.377
, pp. 76-84
-
-
Zahedi, P.1
De Souza, R.2
Piquette-Miller, M.3
Allen, C.4
-
17
-
-
0037331627
-
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group study
-
Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;88:130-5.
-
(2003)
Gynecol Oncol
, vol.88
, pp. 130-135
-
-
Rose, P.G.1
Blessing, J.A.2
Ball, H.G.3
-
18
-
-
0028175036
-
Paclitaxel (Taxol(TM) ) and docetaxel (Taxotere(TM) ): Not simply two of a kind
-
Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol(Tm)) and docetaxel (Taxotere(Tm)) - not simply 2 of a kind. Ann Oncol 1994;5:495-505. (Pubitemid 2112632)
-
(1994)
Annals of Oncology
, vol.5
, Issue.6
, pp. 495-505
-
-
Verweij, J.1
Clavel, M.2
Chevalier, B.3
-
19
-
-
9744223515
-
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherpy for ovarian carcinoma
-
DOI 10.1093/jnci/djh323
-
Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96: 1682-91. (Pubitemid 39585637)
-
(2004)
Journal of the National Cancer Institute
, vol.96
, Issue.22
, pp. 1682-1691
-
-
Vasey, P.A.1
Jayson, G.C.2
Gordon, A.3
Gabra, H.4
Coleman, R.5
Atkinson, R.6
Parkin, D.7
Paul, J.8
Hay, A.9
Kaye, S.B.10
-
20
-
-
0028356485
-
Comparison of paclitaxel and docetaxel activity on human ovarian-carcinoma xenografts
-
Nicoletti MI, Lucchini V, Dincalci M, Giavazzi R. Comparison of paclitaxel and docetaxel activity on human ovarian-carcinoma xenografts. Eur J Cancer 1994;30A:691-6.
-
(1994)
Eur J Cancer
, vol.30 A
, pp. 691-696
-
-
Nicoletti, M.I.1
Lucchini, V.2
Dincalci, M.3
Giavazzi, R.4
-
21
-
-
38649114430
-
Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer
-
Greenaway J, Moorehead R, Shaw P, Petrik J. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol Oncol 2008;108:385-94.
-
(2008)
Gynecol Oncol
, vol.108
, pp. 385-394
-
-
Greenaway, J.1
Moorehead, R.2
Shaw, P.3
Petrik, J.4
-
22
-
-
0033014481
-
Body condition scoring: A rapid and accurate method for assessing health status in mice
-
Ullman-Culleré MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci 1999;49:319-23.
-
(1999)
Lab Anim Sci
, vol.49
, pp. 319-323
-
-
Ullman-Culleré, M.H.1
Foltz, C.J.2
-
23
-
-
33846441659
-
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer
-
Kamat AA, Kim TJ, Landen CN, Jr., et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007;67:281-8.
-
(2007)
Cancer Res
, vol.67
, pp. 281-288
-
-
Kamat, A.A.1
Kim, T.J.2
Landen Jr., C.N.3
-
24
-
-
0347364775
-
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics
-
Morgan RJ, Jr., Doroshow JH, Synold T, et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 2003;9:5896-901.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 5896-5901
-
-
Morgan Jr., R.J.1
Doroshow, J.H.2
Synold, T.3
-
25
-
-
70349668946
-
The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
-
Charles KA, Kulbe H, Soper R, et al. The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009;119:3011-23.
-
(2009)
J Clin Invest
, vol.119
, pp. 3011-3023
-
-
Charles, K.A.1
Kulbe, H.2
Soper, R.3
-
26
-
-
0037314551
-
Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts
-
Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EAG. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 2003;199:221-8.
-
(2003)
J Pathol
, vol.199
, pp. 221-228
-
-
Duan, W.R.1
Garner, D.S.2
Williams, S.D.3
Funckes-Shippy, C.L.4
Spath, I.S.5
Blomme, E.A.G.6
-
27
-
-
28244480457
-
Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis
-
Said N, Motamed K. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 2005;167:1739-52.
-
(2005)
Am J Pathol
, vol.167
, pp. 1739-1752
-
-
Said, N.1
Motamed, K.2
-
28
-
-
34248190133
-
Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: A phase II study
-
Lord R, Nair S, Schache A, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007;177:2136-40.
-
(2007)
J Urol
, vol.177
, pp. 2136-2140
-
-
Lord, R.1
Nair, S.2
Schache, A.3
-
29
-
-
0037093209
-
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water
-
Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
-
(2002)
Cancer Res
, vol.62
, pp. 2731-2735
-
-
Man, S.1
Bocci, G.2
Francia, G.3
-
30
-
-
0035887463
-
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo
-
Bello LS, Carrabba G, Giussani C, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-6.
-
(2001)
Cancer Res
, vol.61
, pp. 7501-7506
-
-
Bello, L.S.1
Carrabba, G.2
Giussani, C.3
-
31
-
-
2942615257
-
The anti-angiogenic basis of metronomic chemotherapy
-
Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 423-436
-
-
Kerbel, R.S.1
Kamen, B.A.2
-
32
-
-
0031719516
-
Role of vascular endothelial growth factor in ovarian cancer - Inhibition of ascites formation by immunoneutralization
-
Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer - inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249-56.
-
(1998)
Am J Pathol
, vol.153
, pp. 1249-1256
-
-
Mesiano, S.1
Ferrara, N.2
Jaffe, R.B.3
-
33
-
-
65649100065
-
Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: HnRNP K as a player
-
Benelli R, Monteghirfo S, Balbi C, Barboro P, Ferrari N. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int J Cancer 2009;124:2989-96.
-
(2009)
Int J Cancer
, vol.124
, pp. 2989-2996
-
-
Benelli, R.1
Monteghirfo, S.2
Balbi, C.3
Barboro, P.4
Ferrari, N.5
-
34
-
-
0037268220
-
Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly
-
Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anti-Cancer Drug 2003;4:13-9.
-
(2003)
Anti-Cancer Drug
, vol.4
, pp. 13-19
-
-
Wang, J.1
Lou, P.2
Lesniewski, R.3
Henkin, J.4
-
35
-
-
0842282637
-
Taxane-mediated antiangiogenesis in vitro: Influence of formulation vehicles and binding proteins
-
Ng SSW, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res 2004;64:821-4.
-
(2004)
Cancer Res
, vol.64
, pp. 821-824
-
-
Ng, S.S.W.1
Figg, W.D.2
Sparreboom, A.3
-
37
-
-
0032789521
-
Determinants of paclitaxel penetration and accumulation in human solid tumor
-
Kuh H-J, Jang SH, Wientjes MG, Weaver JR, Au JL-S. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 1999;290:871-80.
-
(1999)
J Pharmacol Exp Ther
, vol.290
, pp. 871-880
-
-
Kuh, H.-J.1
Jang, S.H.2
Wientjes, M.G.3
Weaver, J.R.4
Au, J.L.-S.5
-
38
-
-
34548463397
-
Identification and quantification of apoptosis in the kidney using morphology, biochemical and molecular markers
-
Hughes J, Gobe G. Identification and quantification of apoptosis in the kidney using morphology, biochemical and molecular markers. Nephrology 2007;12:452-8.
-
(2007)
Nephrology
, vol.12
, pp. 452-458
-
-
Hughes, J.1
Gobe, G.2
-
39
-
-
0033600733
-
The mode of action of Taxol: Apoptosis at low concentration and necrosis at high concentration
-
Yeung TK, Germond C, Chen X, Wang Z. The mode of action of Taxol: apoptosis at low concentration and necrosis at high concentration. Biochem Biophys Res Commun 1999;263:398-404.
-
(1999)
Biochem Biophys Res Commun
, vol.263
, pp. 398-404
-
-
Yeung, T.K.1
Germond, C.2
Chen, X.3
Wang, Z.4
-
40
-
-
60649100252
-
Cancer stem cells and tumor response to therapy: Current problems and future prospects
-
Milas L, Hittelman WN. Cancer stem cells and tumor response to therapy: current problems and future prospects. Semin Radiat Oncol 2009;19:96-105.
-
(2009)
Semin Radiat Oncol
, vol.19
, pp. 96-105
-
-
Milas, L.1
Hittelman, W.N.2
-
41
-
-
0030739859
-
A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer
-
Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-36.
-
(1997)
Radiother Oncol
, vol.44
, pp. 123-136
-
-
Dische, S.1
Saunders, M.2
Barrett, A.3
Harvey, A.4
Gibson, D.5
Parmar, M.6
-
42
-
-
0344738570
-
Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: Pilot study
-
Davis AJ, Chapman W, Hedley DW, Oza AM, Tannock IF. Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study. Cytom Part A 2003;51A:1-6.
-
(2003)
Cytom Part A
, vol.51
, pp. 1-6
-
-
Davis, A.J.1
Chapman, W.2
Hedley, D.W.3
Oza, A.M.4
Tannock, I.F.5
-
43
-
-
0032930199
-
Paclitaxel (taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer
-
Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999;14:31-6.
-
(1999)
Cancer Biother Radiopharm
, vol.14
, pp. 31-36
-
-
Lau, D.H.1
Xue, L.2
Young, L.J.3
Burke, P.A.4
Cheung, A.T.5
|